Insights Into Radiopharmaceuticals: Global Clinical Research Overview

Discover key insights and emerging trends in radiopharmaceuticals from our 2024 clinical trial landscape white paper, addressing questions about these advanced cancer therapies.

Radiopharmaceutical therapy uses radioactive substances to precisely target and destroy cancer cells, distinguishing it from traditional radiation therapy by minimizing damage to healthy tissue. Significant advancements include FDA approval of Pluvicto™ for prostate cancer, marking a milestone in targeted radioligand therapy. Clinical trials have surged globally, supported by increased funding and strategic investments, enhancing treatment options, and expanding research into alpha-emitting radiopharmaceuticals like radium-223.